Clinical Trial Search

Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19

Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121

Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05

Primary: Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h) — 6307; 9791 ng*h/mL

Primary: Left Ventricular Global Strain Rate — 18; 23 percentage of change

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants

Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL

Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants

Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size

Primary: Myocardial Glucose Uptake. — 7.46; 7.22; 0.05; 20.89 umol/min/100g

Primary: High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure) — 106.84; 107.65; 184.30 mg*day/L

Primary: Treatment Evaluation Inventory-Short Form (TEI-SF) — 3.62; 4.00; 3.94; 3.69 units on a scale